ArticleDermatology practical & conceptual2025
Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study.
Article in Dermatology practical & conceptual, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Systemic Immune-Inflammation Index (SII) as a Predictive Biomarker of Therapeutic Response in Psoriasis: A Retrospective Comparative Analysis of Anti-TNF, Anti-IL-17, and Anti-IL-23 Agents.Journal of personalized medicine · 2026Article
- Biologic therapy in geriatric psoriasis: 6-month real-world data on PASI, inflammatory indices, and hepatitis B/tuberculosis safety.Biomolecules & biomedicine · 2026Article
- Long-Term Impact of Guselkumab on Systemic Inflammation Indices in Moderate-to-Severe Psoriasis.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWhole blood cells and derived indices can be used as a read-out of the inflammatory pathogenic processes in many human diseases, including psoriasis. Indeed, systemic treatments with special regard to anti-IL-23 agents could exert anti-inflammatory and disease modifying effects; however, there is still a lack of conclusive data.
objectivesWe aimed to assess the therapeutic effect of risankizumab on whole blood cells and inflammatory indices in psoriatic patients.
methodsWe performed a prospective multicenter observational study on adult patients with moderate-to-severe psoriasis who underwent risankizumab therapy for at least 52 weeks. Blood cell count, CRP, and ESR were prospectively recorded for each patient included in the study, at routine visits up to week 52. The ratio between peripheral cells, namely NLR, PLR, MLR, SII, and PIV, were calculated and compared at time 0 and at weeks 12, 24, and 52 of treatment. At different timepoints, modulation of laboratory values and derived indices and their correlation with disease severity and response to treatment were analyzed. Subanalysis of very early responders and late responders was performed as well.
resultsWe observed a progressive reduction in inflammatory indices such as CRP, ESR, NLR, and SII during treatment, with prominent modification involving SIRI as well, in patients who had a very early and almost complete response to risankizumab. Reduction in neutrophils and MPV, a transient increase in eosinophils at week 12, and a progressive increase in peripheral basophils were associated with therapeutic response.
conclusionRisankizumab promotes a progressive anti-inflammatory effect, more prominent in patients with a faster response in the early phases of treatment.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.